Your browser doesn't support javascript.
loading
Effect of Body Composition on Outcomes in Patients with Hepatocellular Carcinoma Undergoing Radiotherapy: A Retrospective Study.
Li, Li-Qing; Zhao, Wei-Dong; Su, Ting-Shi; Wang, Yu-Dan; Meng, Wan-Wan; Liang, Shi-Xiong.
  • Li LQ; Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Guangxi Zhuang Autonomous Region, Nanning, China.
  • Zhao WD; Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Guangxi Zhuang Autonomous Region, Nanning, China.
  • Su TS; Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Guangxi Zhuang Autonomous Region, Nanning, China.
  • Wang YD; Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Guangxi Zhuang Autonomous Region, Nanning, China.
  • Meng WW; Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Guangxi Zhuang Autonomous Region, Nanning, China.
  • Liang SX; Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Guangxi Zhuang Autonomous Region, Nanning, China.
Nutr Cancer ; 74(9): 3302-3311, 2022.
Article en En | MEDLINE | ID: mdl-35543186
Computed tomography (CT)-assessed body composition is considered a novel prognostic factor for cancer patients. Owing to the need for new prognostic markers for hepatocellular carcinoma (HCC) patients undergoing radiotherapy, we investigated the impact of body composition on outcomes in this patient population. We retrospectively evaluated 109 HCC patients receiving radiotherapy. The skeletal muscle index, subcutaneous adipose tissue index (SATI), and visceral adipose tissue index within 1 mo, before radiotherapy were assessed based on a single CT image slice at the level of the third lumbar (L3) vertebra. The impact of body composition parameters on progression-free survival (PFS) and overall survival (OS) was assessed. Overall, 62 (56.9%) patients died, and 47 (43.1%) patients experienced recurrence during a median follow-up period of 20.5 mo. Multivariate analysis revealed that SATI was an independent prognostic factor for both PFS (hazard ratio [HR] 0.542, P = 0.025) and OS (HR 0.385, P = 0.005). Patients with high SATI (n = 43) had significantly better PFS (P = 0.0093) and OS (P = 0.032) than those with low SATI (n = 66). CT-assessed SATI is an independent prognostic factor in HCC patients receiving radiotherapy. Further validation is warranted to determine whether this finding can be translated into other study populations.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article